Results 51 to 60 of about 232,812 (303)

Next Questions: Multiple Myeloma

, 2021
The multiple myeloma field is moving forward quickly. In the past 12 months, many new insights have been generated through preclinical and clinical studies.
Landgren, C. Ola
core   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

, 2010
BACKGROUND: Thalidomide plus dexamethasone (TD) is a standard induction therapy for myeloma. We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) versus TD alone as induction therapy before, and consolidation therapy after ...
Gimema, Italian Myeloma Network, RUSSO, Domenico, Cavo M, Tacchetti P   +2 more
core   +1 more source

Multiple Myeloma [PDF]

Hematology, 2002
AbstractThis update provides new insights into the biology, diagnosis, prognosis, and treatment of multiple myeloma (MM) and its complications.In Section I, Drs. John Shaughnessy, Jr., and Bart Barlogie first correlate global gene microarray expression profiling of patient MM samples with normal plasma cells to provide the basis for a developmental ...
Kenneth C, Anderson, John D, Shaughnessy, Bart, Barlogie, Jean-Luc, Harousseau, G David, Roodman   +4 more
openaire   +2 more sources

Proteogenomic Profiling of Idiopathic Pulmonary Arterial Hypertension Identifies Sex‐Differential Proteins and Candidate Therapeutic Targets

Advanced Science, EarlyView.
An integrated proteogenomic analysis of 44,137 predominantly European‐ancestry UK Biobank participants aged 40–69 years identifies 12 robust proteins associated with idiopathic pulmonary arterial hypertension. These proteins define a high‐mortality molecular endotype, support early detection and mortality prediction, reveal sex‐differential proteomic ...
Xinjie Lin, Yangchang Zhang, Yang Pu, Duanke Liu, Tao Lei, Kai Ma, Qiyu He, Zheng Dou, Yuze Liu, Dengyuan Liu, Yinge He, Yanshang Wang, Xiaojiao Zheng, Yanbing Ma, Jianrong Zhou, Weiding Zhai, Binbin Su, Li Chen, Shoujun Li   +18 more
wiley   +1 more source

P1222: PACIFIC: BRENTUXIMAB VEDOTIN AND NIVOLUMAB ALONE AND THEN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN AND PREDNISONE FOR UNTREATED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA PATIENTS

HemaSphere, 2022
R. Steiner, P. Strati, C. Flowers, S. Neelapu, M. Green, L. Nastoupil, F. Hagemeister, L. Feng, S. Ahmed, R. Nair, L. Fayad, H. Lee, M. A. Rodriguez, J. Westin   +13 more
doaj   +1 more source

greenelab/multiple-myeloma-classifier: Reproducible Analysis for Multiple Myeloma Classifier

, 2019
Reproducible Analysis for Multiple Myeloma Classifier <p>The release stores all instructions to reproduce the analysis for the training and evaluating of a multi-class classifier to detect <em>KRAS</em>, <em>NRAS</em>, and ...
Greg Way
core   +1 more source

Mitochondrial Localization of Cx26 Promotes Colorectal Cancer Malignancy and Exposes a Fatal Vulnerability to Drug Targeting

Advanced Science, EarlyView.
Mitochondrial localization of Cx26 emerges as a double‐edged sword in colorectal cancer. PIMT‐mediated methylation of Cx26 promotes its mitochondrial localization and stability. Mitochondrial Cx26 then facilitates ER‐mitochondria communication and Ca2+ signaling, thereby promoting metastatic progression. Bortezomib exploits this malignant adaptation by
Jie Wang, Lu Chen, Jia Qin, Xiaoning Wang, Sunlan Ye, Ning An, Mei Bai, Yan Shen, Xuefeng Wu, Qiang Xu   +9 more
wiley   +1 more source

P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY

HemaSphere, 2022
R. Mina, F. Bonello, F. Fazio, R. Saccardi, V. Bongarzoni, F. Marchesi, G. Bertuglia, P. Curci, R. M. Lemoli, S. Ballanti, T. Dentamaro, G. Benevolo, A. Capra, R. Floris, P. Tosi, A. Olivieri, D. Rota-Scalabrini, C. Cangialosi, M. Cavo, P. Corradini, G. Milone, M. Boccadoro, A. Larocca   +22 more
doaj   +1 more source

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

Antibodies, 2017
2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho, Liang Lin, Lijie Xing, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Yu-Tzu Tai   +6 more
doaj   +1 more source